A Phase 1a Study of PMN310 In Healthy Volunteers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-18

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This first in human Phase 1a clinical trial will evaluate the safety, tolerability, and pharmacokinetics of a single IV infusion of PMN310 in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

NCT04184063

Progressive Supranuclear Palsy Multiple System Atrophy

COMPLETED PHASE2

NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa

NCT05083260

Parkinson Disease

COMPLETED PHASE1/PHASE2

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906

Parkinson Disease

COMPLETED PHASE1

A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease

NCT00866502

Parkinson's Disease

COMPLETED PHASE1/PHASE2

A Study of NE3107 in Early Parkinson's

NCT06757010

Parkinsons Disease (PD)

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of intravenous PMN310 in healthy adult volunteers.

Subjects will be randomly assigned to receive either a single infusion of PMN310 or placebo. After randomization on Day 1, study drug will be administered followed by the collection of safety, tolerability, and PK data.

All dose cohorts will have lumbar punctures (LPs) for PK analysis performed on Day 3 and Day 29. Primary PK and CSF data will be obtained from Day 1 to Day 29. Safety and tolerability will be collected at all visits. The study is an 85-day study with one optional follow up assessment at Day 120.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

There will be 5 sequential escalating dose cohort groups. Dose groups are 175 mg, 350 mg, 700 mg, 1400 mg and 2800 mg (optional) administered as a single 60-minute infusion.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double blind

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PMN310

60-minute intravenous infusion

Intervention Type DRUG

Placebo

60-minute intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Female subjects of childbearing potential must not be breastfeeding and must have no plans to become pregnant during the course of the study through 120 days after infusion of study drug.
2. Female subjects of non-childbearing potential must have evidence from their medical history indicating that they are not of childbearing potential.
3. Any non-vasectomized male subjects must agree to use barrier contraceptives (male or female partner condom, diaphragm, cervical cap, sponges) plus spermicide.
4. Medically healthy with no clinically significant or relevant abnormalities in medical history, physical exam, vital signs, ECG, or laboratory evaluations.
5. Has provided written informed consent.
6. Body mass index is between 18 and 32 kg/m2 (inclusive).
7. Screening MRI normal.

Exclusion Criteria

1. Clinically significant 12-lead ECG abnormality at Screening.
2. Systolic blood pressure \> 150 bpm or diastolic blood pressure \> 90 bpm at Screening.
3. Experienced a significant systemic illness within 30 days of the first dose of study drug.
4. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
5. Currently using any medication except for acetaminophen as needed for miscellaneous aches and pains.
6. History of alcohol abuse and/or illicit drug use within 12 months prior dosing or a smoking history (use of tobacco products).
7. Unwilling to refrain from ingesting alcohol within the limits required by the Study.
8. Positive urine drug screen.
9. History of prior malignancy.
10. Documented history of human immunodeficiency virus (HIV) antibody or tested positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at Screening.
11. Donated blood or blood products (e.g., plasma, platelets) within 28 days prior to first dose.
12. Received an investigational agent within the last 30 days or 5 half-lives (if known) prior to Screening, whichever is longer.
13. Contraindication to brain venipuncture, MRI or LP.
14. Indication of potential suicidality risk as identified by the following Columbia-Suicide Severity Rating Scale (C SSRS).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years